Evidence map›Paper›PMID 41060361›Full record

ReviewPediatric dermatology

Omalizumab for Pediatric Cutaneous Mastocytosis: Case Report and Review.

Janis Chang, Aliyah King, Adam Byrne, Carmen Liy-Wong

Abstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pediatric dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Janis ChangDivision of Dermatology, The Ottawa Hospital and University of Ottawa, Ottawa, Canada.
Aliyah KingDepartment of Medicine, University of Ottawa, Ottawa, Canada.ORCID https://orcid.org/0009-0009-3342-265X
Adam ByrneDivision of Infectious Diseases, Allergy, and Immunology, Department of Pediatrics, University of Ottawa, Ottawa, Canada.
Carmen Liy-WongDivision of Dermatology and Rheumatology, Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, Canada.ORCID https://orcid.org/0000-0002-4471-5281

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report an 11-month-old boy with diffuse cutaneous mastocytosis whose severe pruritus and steroid dependence resolved following off-label treatment with omalizumab. A literature review identified five additional pediatric cases in which omalizumab led to complete symptom resolution in an average of 2 months and permitted discontinuation of systemic steroids. Although limited by the small sample size and lack of high-quality data, omalizumab presents as a well-tolerated and potentially effective steroid-sparing agent for pediatric cutaneous mastocytosis.

Indexed as

Anti-Allergic AgentsMastocytosis, CutaneousOmalizumabHumansInfantMaleTreatment OutcomeAnti-Allergic AgentsOmalizumabcase reportmastocytosisomalizumabpediatricssystematic reviewtherapeutic

Identifiers

PMID41060361
PMCPMC13051026

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.